Oligoclonal antibodies to target the ErbB family.

about

Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

P2860

Q36269593-962FAD9B-0BE7-40D0-BB1C-947CBC3647F5

P2860

Oligoclonal antibodies to target the ErbB family.

Item

http://www.wikidata.org/entity/Q35780145

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Oligoclonal antibodies to target the ErbB family.

@ast

Oligoclonal antibodies to target the ErbB family.

@en

type

Item

label

Oligoclonal antibodies to target the ErbB family.

@ast

Oligoclonal antibodies to target the ErbB family.

@en

prefLabel

Oligoclonal antibodies to target the ErbB family.

@ast

Oligoclonal antibodies to target the ErbB family.

@en

P1476

Oligoclonal antibodies to target the ErbB family.

@en

P2093

Jimson W D'Souza

http://www.w3.org/2001/XMLSchema#string

Matthew K Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

P304

1015-1021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.1042362

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25936923

http://www.w3.org/2001/XMLSchema#string

P932

4480362

http://www.w3.org/2001/XMLSchema#string

Oligoclonal antibodies to target the ErbB family.

about

P2860

P2860

Oligoclonal antibodies to target the ErbB family.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932